Cover Image
市場調查報告書

非酒精性脂肪性肝炎的全球市場:2016∼2020年

Global Non-alcoholic Steatohepatitis Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357748
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
非酒精性脂肪性肝炎的全球市場:2016∼2020年 Global Non-alcoholic Steatohepatitis Market 2016-2020
出版日期: 2016年05月06日 內容資訊: 英文 70 Pages
簡介

非酒精性脂肪性肝炎同時也被稱為脂肪浸潤性肝炎,特徵是肝臟內脂肪積蓄。該疾病會引起肝臟嚴重發炎,使臟器受損。肥胖、糖尿病、血脂異常症、胰島素抗性、藥劑造成的毒性都有引起非酒精性肝炎的可能性。全球非酒精性脂肪性肝炎市場在2016∼2020年這段期間預測將以年複合成長率24.58%擴大。

本報告提供全球非酒精性脂肪性肝炎市場現狀與到2020年前的成長預測,彙整市場趨勢與課題,各地區趨勢,主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 對疾病的認識
  • 症狀和前兆
  • 病理學
  • 風險因素
  • 診斷
  • 治療
  • 流行病學
  • 經濟負擔

第6章 開發平台分析

  • 開發平台資訊
  • 臨床實驗

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各劑型市場區隔

  • 固體
  • 液體

第9章 各給藥途徑市場區隔

  • 口服
  • 非口服

第10章 各地區市場市場區隔

  • 各地區市場區隔
  • 南北美洲
  • 美國
  • 歐洲·中東·非洲
  • 亞太地區

第11章 推動市場的要素

  • 久坐的生活方式增加
  • 罹患相關的健康狀態
  • 潛力開發平台
  • 重大的醫療未滿足需求

第12章 促進要素的影響

第13章 市場課題

  • 疾病病理學的有限理解
  • 不完全的診斷技術
  • 嚴格的法律規章手續
  • 藥物的副作用

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • Arena Pharmaceuticals
  • AstraZeneca
  • F Hoffmann-La Roche
  • GSK
  • Novo Nordisk
  • Vivus
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR8374

About Non-Alcoholic Steatohepatitis (NASH)

NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH.

Technavio's analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Arena Pharmaceuticals
  • AstraZeneca
  • F Hoffmann-La Roche
  • GSK
  • Novo Nordisk
  • Vivus

Other Prominent Vendors

  • Arisaph Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead
  • Immuron
  • Interceptpharma
  • Raptor Pharmaceutical
  • Shire
  • Tobira Therapeutics
  • Verva
  • Viking Therapeutics

Market driver

  • Increase in sedentary lifestyle
  • For a full, detailed list, view our report

Market challenge

  • Limited understanding of disease pathophysiology
  • For a full, detailed list, view our report

Market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Symptoms and signs
  • Pathophysiology
  • Risk factors
  • Diagnosis
  • Treatment
  • Epidemiology
  • Economic burden

PART 06: Pipeline analysis

  • Pipeline information of NASH
  • Clinical trials for NASH

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by dosage form

  • Solid
  • Liquid

PART 09: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 10: Geographical segmentation

  • Global NASH drugs market by geographical segmentation 2015-2020
  • NASH drugs market in Americas
  • NASH drugs market in US
  • NASH drugs market in EMEA
  • NASH drugs market in APAC

PART 11: Market drivers

  • Increase in sedentary lifestyle
  • Prevalence of associated health conditions
  • Promising pipeline
  • Significant unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges

  • Limited understanding of disease pathophysiology
  • Insufficient diagnostic technology for NASH
  • Stringent regulatory procedure
  • Adverse effects of drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Rise in public awareness
  • Increase in strategic alliances
  • Patient assistance programs
  • Usage of off-label drugs

PART 16: Vendor landscape

  • Competitive scenario
  • Arena Pharmaceuticals
  • AstraZeneca
  • F Hoffmann-La Roche
  • GSK
  • Novo Nordisk
  • Vivus
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Conditions associated with NASH
  • Exhibit 03: Diagnosis of NASH
  • Exhibit 04: Global NASH drugs market: Pipeline portfolio
  • Exhibit 05: Clinical trials for NASH by development phase
  • Exhibit 06: Clinical trials for NASH by trial status
  • Exhibit 07: Global NASH drugs market 2015-2020 ($ millions)
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global NASH drugs market by dosage form
  • Exhibit 10: Segmentation of global NASH drugs market by route of administration
  • Exhibit 11: Global NASH drugs market by geographical segmentation 2015
  • Exhibit 12: Global NASH drugs market revenue by geography 2015-2020 ($ millions)
  • Exhibit 13: NASH drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 14: NASH market in US 2015-2020 ($ millions)
  • Exhibit 15: NASH drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 16: NASH drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 17: Impact of drivers
  • Exhibit 18: Impact of drivers and challenges
  • Exhibit 19: Arena Pharmaceuticals: YoY revenue of Belviq 2013-2014 ($ millions)
  • Exhibit 20: Arena Pharmaceuticals: Key takeaways
  • Exhibit 21: AstraZeneca: Cardiovascular and metabolic diseases segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 22: Top selling products in 2014 ($ millions)
  • Exhibit 23: AstraZeneca: YoY growth and revenue of Bydureon 2012-2014 ($ millions)
  • Exhibit 24: AstraZeneca: YoY growth and revenue of Byetta 2012-2014 ($ millions)
  • Exhibit 25: AstraZeneca: YoY growth and revenue of Onglyza/ Komboglyze/ Komboglyze XR 2012-2014 ($ millions)
  • Exhibit 26: AstraZeneca: Key takeaways
  • Exhibit 27: Roche: Key takeaways
  • Exhibit 28: GSK: Key takeaways
  • Exhibit 29: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 30: Novo Nordisk: R&D expenditure 2014
  • Exhibit 31: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2012-2014 ($ millions)
  • Exhibit 32: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2012-2014 ($ millions)
  • Exhibit 33: Novo Nordisk: YoY growth and revenue of Prandin 2012-2014 ($ millions)
  • Exhibit 34: Novo Nordisk: Key takeaways
  • Exhibit 35: Vivus: YoY growth and revenue of Qsymia 2012-2014 ($ millions)
  • Exhibit 36: Vivus: Key takeaways
Back to Top